Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hugel, Inc. (145020.KQ)
Chuncheon-si, KR
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.92% | +9.14% | +10.00% | +6.45% | +24.67% | +19.36% | -18.22% | +151.34% | +33.95% | +153.31% | +400.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+14.0% ★ Q1'26: +29.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-6.9% Q1'26: +20.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+26.5% Q1'26: +51.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+47.2% ★ Q1'26: +40.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+31.6% ★ Q1'26: +29.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.8% Q1'26: +15.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.13× ★ Q1'26: 0.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 9 EPS Ana. |
Dec 2027 14 Rev. Ana. 13 EPS Ana. |
Dec 2028 6 Rev. Ana. 9 EPS Ana. |
Dec 2029 9 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
319.70B
est: 321.74B (-0.6%)
|
373.05B
est: 377.09B (-1.1%)
|
425.11B
est: 420.71B (+1.0%)
|
509.54B
494.98B – 524.86B
+21.1% YoY
|
618.06B
514.75B – 673.48B
+21.3% YoY
|
728.71B
652.95B – 774.25B
+17.9% YoY
|
947.00B
848.54B – 1.01T
+30.0% YoY
|
| EBITDA |
131.60B
est: 140.47B (-6.3%)
|
181.39B
est: 227.30B (-20.2%)
|
220.29B
est: 253.59B (-13.1%)
|
307.14B
298.36B – 316.38B
+21.1% YoY
|
372.55B
310.28B – 405.96B
+21.3% YoY
|
439.25B
393.58B – 466.70B
+17.9% YoY
|
570.83B
511.48B – 606.50B
+30.0% YoY
|
| EBIT |
117.74B
est: 124.65B (-5.5%)
|
166.36B
est: 215.75B (-22.9%)
|
200.54B
est: 240.71B (-16.7%)
|
291.54B
283.20B – 300.30B
+21.1% YoY
|
353.62B
294.52B – 385.33B
+21.3% YoY
|
416.93B
373.59B – 442.99B
+17.9% YoY
|
541.83B
485.50B – 575.69B
+30.0% YoY
|
| Net Income |
93.08B
est: 90.74B (+2.6%)
|
135.81B
est: 144.50B (-6.0%)
|
140.87B
est: 152.14B (-7.4%)
|
176.20B
158.66B – 202.75B
+15.8% YoY
|
228.66B
171.84B – 282.13B
+29.8% YoY
|
285.44B
246.86B – 308.63B
+24.8% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
109.47B
est: 62.62B (+74.8%)
|
60.13B
est: 75.88B (-20.8%)
|
63.86B
est: 84.65B (-24.6%)
|
102.53B
99.60B – 105.61B
+21.1% YoY
|
124.36B
103.58B – 135.51B
+21.3% YoY
|
146.63B
131.38B – 155.79B
+17.9% YoY
|
190.55B
170.74B – 202.46B
+30.0% YoY
|
| EPS |
8,217.00
est: 8,045.52 (+2.1%)
|
12,520.00
est: 11,254.93 (+11.2%)
|
11,215.00
est: 11,849.57 (-5.4%)
|
13,723.61
12,357.80 – 15,791.42
+15.8% YoY
|
17,809.73
13,384.34 – 21,974.07
+29.8% YoY
|
22,232.41
19,227.57 – 24,038.49
+24.8% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eva Huang | Managing Director | 612M | female |
| Daniel Chang | Head of Hugel Korea | — | — |
| J. T. Kim | MD & Chief Financial Officer | — | — |
| Jennifer Rho | MD & Chief Strategy Officer | — | — |
| Ji-hye Noh | Senior Managing Director of Communication department | — | — |
| Jihye Song | MD & Head of Cosmetics | — | — |
| Seonho Han | Vice President and Chief Sales & Marketing Officer | — | — |
| Soon-Woo Kwon | Vice President & Chief Production Officer | — | male |
| Carrie C. Strom | President & Global Chief Executive Officer | — | female |
| Young Mahn Yoo | MD & Chief Production Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 145020.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
